Handelen Madrigal Pharmaceuticals, Inc. - MDGL CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.79 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Madrigal Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 268.45 |
| Open* | 269.89 |
| 1-Jaarlijkse Verandering* | 308.99% |
| Dagelijks bereik* | 255.84 - 269.89 |
| 52 wekelijks bereik | 57.21-322.67 |
| Weekgemiddelde volume (10 dagen) | 287.96K |
| Gemiddeld volume (3 maanden) | 8.07M |
| Marktkapitalisatie | 4.92B |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 18.29M |
| Omzet | N/A |
| EPS | -18.09 |
| Dividend (opbrengst %) | N/A |
| Beta | -0.71 |
| Volgende inkomsten datum | Aug 2, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 259.68 | -8.70 | -3.24% | 268.38 | 271.04 | 255.27 |
| Jun 1, 2023 | 268.45 | -7.38 | -2.68% | 275.83 | 282.74 | 265.78 |
| May 31, 2023 | 277.89 | -1.37 | -0.49% | 279.26 | 281.77 | 276.10 |
| May 30, 2023 | 279.81 | -5.01 | -1.76% | 284.82 | 288.35 | 278.54 |
| May 26, 2023 | 284.31 | 2.89 | 1.03% | 281.42 | 287.91 | 277.93 |
| May 25, 2023 | 281.41 | -10.91 | -3.73% | 292.32 | 292.82 | 276.84 |
| May 24, 2023 | 291.74 | 11.88 | 4.24% | 279.86 | 300.24 | 278.00 |
| May 23, 2023 | 281.98 | -0.86 | -0.30% | 282.84 | 302.10 | 279.87 |
| May 22, 2023 | 284.82 | 8.29 | 3.00% | 276.53 | 286.40 | 273.83 |
| May 19, 2023 | 276.44 | -1.72 | -0.62% | 278.16 | 279.97 | 272.97 |
| May 18, 2023 | 276.30 | 0.37 | 0.13% | 275.93 | 276.69 | 270.05 |
| May 17, 2023 | 277.72 | -11.99 | -4.14% | 289.71 | 293.00 | 275.89 |
| May 16, 2023 | 291.85 | 12.90 | 4.62% | 278.95 | 294.03 | 269.93 |
| May 15, 2023 | 289.76 | -2.56 | -0.88% | 292.32 | 297.84 | 288.99 |
| May 12, 2023 | 292.61 | 6.14 | 2.14% | 286.47 | 293.86 | 285.57 |
| May 11, 2023 | 287.59 | -2.38 | -0.82% | 289.97 | 294.32 | 281.69 |
| May 10, 2023 | 291.96 | -6.36 | -2.13% | 298.32 | 301.67 | 289.73 |
| May 9, 2023 | 298.99 | -2.82 | -0.93% | 301.81 | 310.90 | 268.85 |
| May 8, 2023 | 308.46 | 2.70 | 0.88% | 305.76 | 312.81 | 299.81 |
| May 5, 2023 | 306.18 | 0.34 | 0.11% | 305.84 | 308.86 | 297.82 |
Madrigal Pharmaceuticals, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Tijd (UTC) (UTC) 18:30 | Land US
| Evenement Madrigal Pharmaceuticals Inc at Jefferies Healthcare Conference Madrigal Pharmaceuticals Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Thursday, June 15, 2023 | ||
| Tijd (UTC) (UTC) 13:00 | Land US
| Evenement Madrigal Pharmaceuticals Inc Annual Shareholders Meeting Madrigal Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Tijd (UTC) (UTC) 14:00 | Land US
| Evenement Madrigal Pharmaceuticals Inc Annual Shareholders Meeting Madrigal Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 2, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q2 2023 Madrigal Pharmaceuticals Inc Earnings Release Q2 2023 Madrigal Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q3 2023 Madrigal Pharmaceuticals Inc Earnings Release Q3 2023 Madrigal Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 293.571 | 242.482 | 206.673 | 94.972 | 40.682 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 48.13 | 37.318 | 21.864 | 22.648 | 15.293 |
| Onderzoek & Ontwikkeling | 245.441 | 205.164 | 184.809 | 72.324 | 25.389 |
| Bedrijfsresultaat | -293.571 | -242.482 | -206.673 | -94.972 | -40.682 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -1.779 | 0.363 | 4.329 | 11.024 | 7.671 |
| Netto inkomen voor belastingen | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
| Netto inkomen na belastingen | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
| Netto inkomen voor extra. Posten | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
| Netto inkomen | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
| Verwaterd Netto Inkomen | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
| Verwaterd Gewogen Gemiddelde Aandelen | 17.1372 | 16.5352 | 15.4466 | 15.3947 | 14.7967 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -17.2344 | -14.6261 | -13.0931 | -5.45306 | -2.21745 |
| Verwaterde Genormaliseerde Winst per Aandeel | -17.2344 | -14.6261 | -13.0931 | -5.45306 | -2.21745 |
| Overige, Netto | 0 | 0.273 | 0.1 | 0 | 0.2 |
| Totale buitengewone posten | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 78.336 | 85.299 | 80.412 | 70.273 | 57.587 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 16.182 | 14.557 | 12.141 | 11.774 | 9.658 |
| Onderzoek & Ontwikkeling | 62.154 | 70.742 | 68.271 | 58.499 | 47.929 |
| Bedrijfsresultaat | -78.336 | -85.299 | -80.412 | -70.273 | -57.587 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 1.44 | -0.606 | -0.785 | -0.457 | 0.069 |
| Overige, Netto | 0 | 0 | 0 | 0 | |
| Netto inkomen voor belastingen | -76.896 | -85.905 | -81.197 | -70.73 | -57.518 |
| Netto inkomen na belastingen | -76.896 | -85.905 | -81.197 | -70.73 | -57.518 |
| Netto inkomen voor extra. Posten | -76.896 | -85.905 | -81.197 | -70.73 | -57.518 |
| Netto inkomen | -76.896 | -85.905 | -81.197 | -70.73 | -57.518 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -76.896 | -85.905 | -81.197 | -70.73 | -57.518 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -76.896 | -85.905 | -81.197 | -70.73 | -57.518 |
| Verwaterd Netto Inkomen | -76.896 | -85.905 | -81.197 | -70.73 | -57.518 |
| Verwaterd Gewogen Gemiddelde Aandelen | 18.1879 | 17.2386 | 17.1034 | 17.1034 | 17.1034 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -4.22786 | -4.98329 | -4.74742 | -4.13544 | -3.36296 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -4.22786 | -4.98329 | -4.74742 | -4.13544 | -3.36296 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 361.369 | 271.684 | 285.163 | 440.197 | 485.201 |
| Geldmiddelen en kortetermijnbeleggingen | 358.774 | 270.346 | 284.149 | 439.045 | 483.718 |
| Geldmiddelen & Equivalenten | 331.549 | 36.269 | 54.004 | 46.697 | 57.379 |
| Korte Termijn Investeringen | 27.225 | 234.077 | 230.145 | 392.348 | 426.339 |
| Totale Vorderingen, Netto | |||||
| Prepaid Expenses | 2.595 | 1.338 | 1.014 | 1.152 | 1.483 |
| Total Assets | 362.572 | 273.332 | 286.995 | 442.056 | 485.428 |
| Property/Plant/Equipment, Total - Net | 1.203 | 1.648 | 1.832 | 1.859 | 0.227 |
| Total Current Liabilities | 115.894 | 76.838 | 46.557 | 25.13 | 8.444 |
| Accounts Payable | 23.831 | 21.38 | 1.017 | 1.178 | 2.487 |
| Accrued Expenses | 92.063 | 55.458 | 45.54 | 23.952 | 5.957 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 165.183 | 77.225 | 47.025 | 25.491 | 8.444 |
| Total Long Term Debt | 49.289 | 0 | 0 | 0 | 0 |
| Total Equity | 197.389 | 196.107 | 239.97 | 416.565 | 476.984 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Additional Paid-In Capital | 1160.08 | 863.495 | 665.385 | 639.567 | 616.573 |
| Retained Earnings (Accumulated Deficit) | -962.66 | -667.31 | -425.464 | -223.22 | -139.272 |
| Other Equity, Total | -0.032 | -0.08 | 0.047 | 0.216 | -0.319 |
| Total Liabilities & Shareholders’ Equity | 362.572 | 273.332 | 286.995 | 442.056 | 485.428 |
| Total Common Shares Outstanding | 18.1025 | 17.1034 | 15.5082 | 15.4291 | 15.409 |
| Other Liabilities, Total | 0 | 0.387 | 0.468 | 0.361 | |
| Long Term Debt | 49.289 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 331.284 | 361.369 | 157.112 | 214.546 | 221.17 |
| Geldmiddelen en kortetermijnbeleggingen | 329.477 | 358.774 | 153.192 | 211.766 | 219.953 |
| Geldmiddelen & Equivalenten | 113.308 | 331.549 | 41.112 | 51.544 | 40.044 |
| Korte Termijn Investeringen | 216.169 | 27.225 | 93.852 | 158.494 | 177.671 |
| Prepaid Expenses | 1.807 | 2.595 | 3.92 | 2.78 | 1.217 |
| Total Assets | 332.449 | 362.572 | 158.644 | 216.392 | 222.662 |
| Property/Plant/Equipment, Total - Net | 1.165 | 1.203 | 1.532 | 1.846 | 1.492 |
| Total Current Liabilities | 98.348 | 115.894 | 98.92 | 84.009 | 76.635 |
| Accounts Payable | 12.128 | 23.831 | 18.562 | 11.294 | 22.78 |
| Accrued Expenses | 86.22 | 92.063 | 80.358 | 72.715 | 53.855 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 182.313 | 165.183 | 147.974 | 132.857 | 76.918 |
| Total Long Term Debt | 83.965 | 49.289 | 48.983 | 48.67 | 0 |
| Other Liabilities, Total | 0 | 0.071 | 0.178 | 0.283 | |
| Total Equity | 150.136 | 197.389 | 10.67 | 83.535 | 145.744 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Additional Paid-In Capital | 1189.78 | 1160.08 | 887.66 | 879.538 | 870.972 |
| Retained Earnings (Accumulated Deficit) | -1039.56 | -962.66 | -876.755 | -795.558 | -724.828 |
| Other Equity, Total | -0.086 | -0.032 | -0.237 | -0.447 | -0.402 |
| Total Liabilities & Shareholders’ Equity | 332.449 | 362.572 | 158.644 | 216.392 | 222.662 |
| Total Common Shares Outstanding | 18.2831 | 18.1025 | 17.1034 | 17.1034 | 17.1034 |
| Cash | 18.228 | 1.728 | 2.238 | ||
| Long Term Debt | 83.965 | 49.289 | 48.983 | 48.67 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 |
| Geldmiddelen uit Operationele Activiteiten | -224.857 | -183.917 | -157.561 | -41.624 | -25.507 |
| Geldmiddelen uit Operationele Activiteiten | 0.467 | 0.405 | 0.471 | 0.112 | 0.096 |
| Niet-Geldelijke Posten | 32.422 | 26.873 | 20.73 | 22.759 | 13.489 |
| Veranderingen in het Operationeel Kapitaal | 37.604 | 30.651 | 23.482 | 19.453 | -6.281 |
| Geldmiddelen uit Investeringsactiviteiten | 206.686 | -5.055 | 159.78 | 30.707 | -380.076 |
| Kapitaaluitgaven | -0.217 | -0.209 | -0.334 | -0.172 | -0.022 |
| Overige Cash Flow investeringsposten, Totaal | 206.903 | -4.846 | 160.114 | 30.879 | -380.054 |
| Geldmiddelen uit Financieringsactiviteiten | 313.451 | 171.237 | 5.088 | 0.235 | 314.335 |
| Financiering van Cash Flow Posten | -0.886 | 0 | |||
| Uitgifte (Aflossing) van aandelen, netto | 264.337 | 171.237 | 5.088 | 0.235 | 314.335 |
| Nettowijziging in Geldmiddelen | 295.28 | -17.735 | 7.307 | -10.682 | -91.248 |
| Uitgifte (Aflossing) van Schulden, Netto | 50 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.896 | -295.35 | -209.445 | -128.248 | -57.518 |
| Cash From Operating Activities | -84.067 | -224.857 | -166.342 | -107.273 | -49.913 |
| Cash From Operating Activities | 0.124 | 0.467 | 0.338 | 0.217 | 0.107 |
| Non-Cash Items | 11.683 | 32.422 | 24.034 | 15.599 | 7.477 |
| Changes in Working Capital | -18.978 | 37.604 | 18.731 | 5.159 | 0.021 |
| Cash From Investing Activities | -186.864 | 206.686 | 140.299 | 75.162 | 55.926 |
| Capital Expenditures | -0.035 | -0.217 | -0.188 | -0.155 | -0.052 |
| Other Investing Cash Flow Items, Total | -186.829 | 206.903 | 140.487 | 75.317 | 55.978 |
| Cash From Financing Activities | 52.69 | 313.451 | 49.114 | 49.114 | 0 |
| Issuance (Retirement) of Stock, Net | 17.903 | 264.337 | 0 | 0 | 0 |
| Net Change in Cash | -218.241 | 295.28 | 23.071 | 17.003 | 6.013 |
| Financing Cash Flow Items | -0.213 | -0.886 | -0.886 | -0.886 | |
| Issuance (Retirement) of Debt, Net | 35 | 50 | 50 | 50 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 9.1129 | 1666666 | 6666 | 2023-03-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 8.4482 | 1545113 | 0 | 2023-03-31 | LOW |
| Bay City Capital L.L.C. | Venture Capital | 8.266 | 1511782 | 0 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.7419 | 1415928 | 151798 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.6484 | 850147 | -18592 | 2023-03-31 | LOW |
| SQN, L.L.C. | Corporation | 3.5843 | 655540 | 0 | 2023-03-31 | LOW |
| Perceptive Advisors LLC | Private Equity | 3.5571 | 650562 | -81370 | 2023-03-31 | MED |
| Marshall Wace LLP | Investment Advisor/Hedge Fund | 2.9622 | 541764 | 541764 | 2023-03-31 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.8422 | 519814 | -741179 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 2.8246 | 516588 | 392145 | 2023-03-31 | HIGH |
| Craves (Frederick B) | Individual Investor | 2.5663 | 469358 | 0 | 2023-03-31 | LOW |
| Taub (Rebecca A) | Individual Investor | 2.3771 | 434758 | -20001 | 2023-03-31 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 2.0541 | 375674 | 193026 | 2023-03-31 | LOW |
| Rock Springs Capital Management LP | Hedge Fund | 1.9034 | 348121 | 0 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 1.5091 | 276000 | 68000 | 2023-03-31 | HIGH |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.4338 | 262233 | 63743 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3563 | 248057 | 11472 | 2023-03-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 1.1798 | 215770 | 3480 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.9777 | 178815 | 19661 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.9589 | 175382 | 170800 | 2023-03-31 | HIGH |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Madrigal Pharmaceuticals, Inc. Company profile
Over Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf in een klinische fase. Het bedrijf richt zich op de ontwikkeling en commercialisering van therapeutische kandidaten voor de behandeling van cardiovasculaire, metabole en leverziekten. De belangrijkste productkandidaat van de Vennootschap, MGL-3196 (resmetirom), is een op de lever gerichte, selectieve schildklierhormoonreceptor-ß (THR-ß) agonist voor de behandeling van niet-alcoholische steatohepatitis (NASH) en heterozygote familiale hypercholesterolemie (HeFH). De productpijplijn omvat ook MGL-3745, dat wordt gebruikt voor de behandeling van NASH en HeFH.
| Industry: | Bio Therapeutic Drugs |
200 Barr Harbor Dr Ste 400
CONSHOHOCKEN
PENNSYLVANIA 19428-2978
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen